Patent infringement suit
This article was originally published in The Rose Sheet
Executive Summary
DermaQuest Skin Therapy has been dismissed from a patent infringement case by Allergan accusing eight companies of infringing a patent for the drug company's prostaglandin-based drug Lumigan, DermaQuest announces Jan. 11. The suit centers on the defendants' use of an ingredient used in Lumigan that reduces eye pressure in patients with glaucoma, but has the side effect of promoting eyelash growth. Allergan dismissed DermaQuest from the suit after the company proved its DermaLash lash-conditioning product did not contain the ingredient. However, Allergan is pressing on with its case against Jan Marini Skin Research regarding its Age Intervention eyelash products, although the beauty firm maintains it is not infringing any patents (1"The Rose Sheet" Jan. 14, 2008, p. 8)...